Article: What Strategies are Being Employed to Accelerate Product Development and Commercialization Without Compromising Quality
Summary: In this installment of the Pharma’s Almanac quarterly roundtable questionnaire, they asked industry experts to respond to the following prompt: The biopharmaceutical industry faces increasing pressure to reduce time-to-market. What strategies are being employed to accelerate product development and commercialization without compromising quality? Victor Vinci, Ph.D., Global Vice President, Product Development, Catalent Cell, Gene & Protein Therapies responded.
KEY LEARNINGS:
- Catalent is witnessing ongoing benefits from platform approaches in both viral vector and CAR-T process development, production, and analytics.
- A standardized platform approach enables rapid progression to first-in-human studies, accelerating the development process while ensuring safety and efficacy
- Catalent’s UpTempo℠ manufacturing platforms introduce a flexible production environment for cell and gene therapies.